Highlights

• Novartis India shares fell over 6% after a steep rally in recent months.
• Investors appeared to book profits following the stake-sale-driven surge.
• March-quarter profit declined despite growth in revenue from operations.

Overview

Novartis India (NSE: NOVARTIND) came under selling pressure on June 3, with the stock declining 6.18% to ₹1,375.00. The correction follows a substantial rally that lifted the stock to multi-year highs in recent months. The recent decline appears linked to profit booking after the stock's sharp run-up and investor reassessment of recent corporate developments.

Fundamental View

A key factor behind the earlier rally was the announcement that Swiss pharmaceutical giant Novartis AG agreed to sell its 70.68% stake in Novartis India to a consortium led by Waverise Investments Holdings and Eternis Fine Chemicals. The transaction sparked significant investor interest and resulted in a sharp re-rating of the stock. Reuters reported that the deal valued the stake at approximately USD 290 million and would trigger an open offer for public shareholders.

However, after the sharp appreciation, investors appear to be locking in gains. The company's March 2026 quarter results also showed standalone net profit declining to INR 25.25 crore from INR 29.30 crore a year earlier despite revenue growth, which may have contributed to the recent pullback.

Technical View

Novartis India traded at ₹1,375.00 and remained well above its 50-day SMA of ₹1,010.50, indicating that the broader trend remains positive despite the latest correction. Recent price action shows the stock retreating after reaching fresh highs near the ₹1,550 zone.

The 14-day RSI stood at 61.85, cooling from overbought territory. While momentum remains positive, the indicator suggests that the stock is undergoing a normalization phase following its steep advance.

Key Technical Levels

The immediate support zone is placed near ₹1,306.25, followed by a stronger support area around ₹1,237.50. These levels could be important for determining whether the current correction remains contained within the broader uptrend.

On the upside, immediate resistance is seen near ₹1,443.75. A move above this level may bring the recent high zone around ₹1,512.50 back into focus.

Risks to Watch

• Profit booking after the takeover-related rally.
• Regulatory approvals linked to the stake-sale transaction.
• Earnings growth moderation in upcoming quarters.
• Elevated volatility following sharp price appreciation.

Summary

Novartis India shares declined after an extended rally that was largely driven by the announcement of Novartis AG's planned stake sale. While the broader technical trend remains positive and the stock continues to trade comfortably above its 50-day SMA, investors appear to be booking profits following the sharp re-rating. Market participants will likely monitor the progress of the stake-sale transaction and upcoming earnings performance for further direction.

FAQs

Why did Novartis India shares fall today?
The decline appears driven by profit booking after a sharp rally linked to the announced promoter stake sale.

What sparked the earlier rally in Novartis India stock?
The rally followed Novartis AG's agreement to sell its majority stake in Novartis India to a consortium.

Is the long-term trend still positive?
The stock remains above its 50-day SMA, indicating the broader trend remains constructive despite the recent correction.